Invitrogen Corporation and Greiner Bio-One Inc. Team to Increase HPV Test Reliability

CARLSBAD, Calif. & FRICKENHAUSEN, Germany--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for disease research and drug discovery, and Greiner Bio-One, an internationally leading technology partner for the diagnostics and pharmaceutical industry, have finalized a licensing agreement to help improve the reliability of Greiner Bio-One’s HPV-DNA-test PapilloCheck® and DNA-array CytoCheck® products. The agreement covers the rights for the use of dUTP (deoxyuridine triphosphate) in PCR-based (polymerase chain reaction) methods to prevent sample contamination by amplification products in aerosols.